Valuations

Challenge Our client was a privately-held US biotech company developing a proprietary platform technology for in vivo expression of DNA coding for a therapeutic antibody or protein. The approach...

Challenge: A former venture fund client identified a novel Phase 1-ready asset for treating a rare CNS infectious disease and was interested in licensing the asset and founding a new company to...

Challenge: A UK-based pharma company specializing in oncology drug development sought to understand the potential value of a nanoparticle drug product in small cell lung cancer (SCLC). Alacrita was...

Challenge: In preparation for fundraising, a biotech company developing a clinical stage radiolabeled peptide to diagnose pulmonary diseases required an independent valuation of its technology in...

Challenge: An investor and asset manager was considering an investment in a European biotech company with one development product for hemophilia and another approved OTC product in an unrelated...

Challenge A preclinical-stage company developing an integrin-targeting oncology asset engaged Alacrita to quantify the value potential of its lead asset in pancreatic ductal adenocarcinoma (PDAC),...

Challenge A recently emerged biotech company developing prophylactic monoclonal antibodies (mAbs) against a major viral target for immunocompromised patients asked Alacrita to develop an independent...

Challenge A UK-based oncology drug development company was planning to in license a small molecule in development for hepatocellular carcinoma (HCC) and Rhabdomyosarcoma. Alacrita was commissioned to...

Challenge A preclinical stage biotech company developing a novel formulation of insulin to treat diabetes mellitus was in discussions with prospective investors for a next round of funding. To...

Challenge An investment firm required independent valuations of five therapeutics within two of its portfolio companies, including four preclinical programs and a proprietary formulation of a...

Challenge A biotech company had developed preclinical data supporting the use of its lead drug candidate in enhancing male fertility. The product was being considered for both ex-vivo usage prior to...

Challenge A clinical stage immuno-oncology biotech company spun out from a leading university had completed a Phase I clinical trial in ovarian cancer patients with its lead antibody. In response to...